Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China

被引:13
|
作者
Zhong, Yu-Ping [1 ]
Zhang, Yi-Zhuo [2 ]
Liao, Ai-Jun [3 ]
Li, Su-Xia [4 ]
Tian, Chen [5 ]
Lu, Jin [6 ,7 ]
机构
[1] Beijing Univ, Clin Res Inst, Capital Med Univ, Dept Hematol,Beijing Chaoyang Hosp West, Beijing 100043, Peoples R China
[2] Tianjin Med Univ, Dept Hematol, Canc Inst & Hosp, Tianjin Canc Hosp, Tianjin 300000, Peoples R China
[3] China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang 110004, Liaoning, Peoples R China
[4] Peoples Liberat Army 301 Hosp, Dept Hematol, Beijing 100853, Peoples R China
[5] Peoples Liberat Army 304 Hosp, Dept Hematol, Beijing 100048, Peoples R China
[6] Peking Univ, Peoples Hosp, Dept Hematol, 11 Xizhimen South St, Beijing 100044, Peoples R China
[7] Peking Univ, Inst Hematol, 11 Xizhimen South St, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
Geriatric Assessment; Multicenter Study; Multiple Myeloma; QUALITY-OF-LIFE; THALIDOMIDE; METAANALYSIS; REGIMENS;
D O I
10.4103/0366-6999.197977
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elderly multiple myeloma (MM) patients often tend to suffer a variety of diseases, so the treatment of choice is very difficult for the elderly myeloma patients. The overall survival (OS) time and side effects with elderly patients are unclear in China. The study tried to find out the role of geriatric assessment in the Chinese elderly MM. Methods: We retrospectively analyzed the data of 628 newly diagnosed patients from six hospitals from June 2011 to June 2013. A geriatric assessment had been performed to assess comorbidities, cognitive, and physical status for these patients. The primary endpoint was to evaluate different physical states of elderly patients with OS time and treatment-related side effects. Results: An additive scoring system (range: 0-5), based on age, Katzs Activity of Daily Living (ADL) and Lawtons Instrumental Activity of Daily Living (IADL) %5 and Charlson Comorbidity Index (CCI) was developed to identify three groups: fit (score = 0); intermediate-fitness (score = 1); and frail (score >= 2). The 3-year OS was 63% in fit patients, 63% in intermediate-fitness patients, and 49% in frail patients >= 3 hematologic adverse events (AEs) were documented in 45 (35.4%) fit, 34 (34%) intermediate-fitness, and 121 (30.2%) frail patients. The risk of a grade >= 3 hematologic AEs was not significantly increase in intermediate-fitness (hazard ratios [HR]: 0.99, 95% confidence interval [CI]: 0.54-1.47, P = 1.000) and in frail patients (HR: 1.16, 95% CI: 0.70-1.93, P = 0.558) compared with fit ones. Conclusions: MM occurs earlier in life and being advanced when the diagnosis is made in the mainland of China. The overall survival in frailty with International Staging System (ISS) II/III was the worst in all patients.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
  • [41] A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma
    Straube, Christoph
    Kessel, Kerstin A.
    Antoni, Stefanie
    Gempt, Jens
    Meyer, Bernhard
    Schlegel, Juergen
    Schmidt-Graf, Friederike
    Combs, Stephanie E.
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [42] A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma
    Christoph Straube
    Kerstin A. Kessel
    Stefanie Antoni
    Jens Gempt
    Bernhard Meyer
    Juergen Schlegel
    Friederike Schmidt-Graf
    Stephanie E. Combs
    Radiation Oncology, 15
  • [43] Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma
    Ozaki, Shuji
    Handa, Hiroshi
    Saitoh, Takayuki
    Sunami, Kazutaka
    Ishida, Tadao
    Suzuki, Kenshi
    Narita, Tomoko
    Iida, Shinsuke
    Nakamura, Yuichi
    Suzuki, Kazuhito
    Nishimura, Noriko
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    BLOOD, 2019, 134
  • [44] Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Yu, Yuan-Bin
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Chiou, Tzeon-Jye
    Liu, Jin-Hwang
    Liu, Yao-Chung
    Liu, Chia-Jen
    MEDICINE, 2015, 94 (50)
  • [45] Risk of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma
    Liu, Chia-Jen
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Yu, Yuan-Bin
    Chiou, Tzeon-Jye
    Liu, Yao-Chung
    Liu, Jing-Hwang
    BLOOD, 2015, 126 (23)
  • [46] Comprehensive geriatric assessment to predict adverse events in elderly patients undergoing posterior lumbar fusion surgery
    Peng Cui
    Ting Liu
    Zheng Wang
    Shuaikang Wang
    Peng Wang
    Chao Kong
    Shibao Lu
    European Spine Journal, 2024, 33 : 274 - 281
  • [47] Comprehensive geriatric assessment to predict adverse events in elderly patients undergoing posterior lumbar fusion surgery
    Cui, Peng
    Liu, Ting
    Wang, Zheng
    Wang, Shuaikang
    Wang, Peng
    Kong, Chao
    Lu, Shibao
    EUROPEAN SPINE JOURNAL, 2024, 33 (01) : 274 - 281
  • [48] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
    Bringhen, Sara
    Petrucci, Maria Teresa
    Larocca, Alessandra
    Conticello, Concetta
    Rossi, Davide
    Magarotto, Valeria
    Musto, Pellegrino
    Boccadifuoco, Luana
    Offidani, Massimo
    Omede, Paola
    Gentilini, Fabiana
    Ciccone, Giovannino
    Benevolo, Giulia
    Genuardi, Mariella
    Montefusco, Vittorio
    Oliva, Stefania
    Caravita, Tommaso
    Tacchetti, Paola
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2014, 124 (01) : 63 - 69
  • [49] Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Zhang, Yue
    Chen, Xiao-Lei
    Chen, Wen-Ming
    Zhou, He-Bing
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [50] Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
    Nandakumar, Bharat
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis K.
    Lacy, Martha Q.
    Gertz, Morie A.
    Dispenzieri, Angela
    Dingli, David
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Hayman, Suzanne R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Warsame, Rahma M.
    Siddiqui, Mustaqeem A.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2020, 136